The Spanish association for Creutzfeldt-Jakob disease (AECJD) gathers patients and relatives dealing with devastating prion disorders and aims to contribute to a cure by promoting research activities. For that purpose, the members have organized several fundraising activities and opened a call for researchers all over Spain to apply to ‘Cristina Pericàs Almendro’ 2018-2019 research grant. This year, ATLAS Molecular Pharma has been awarded with 20.000 € to further advance on its research on a therapy for prion diseases that include Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome and Fatal familial insomnia. Starting on April 2018, the results of the project will be reported annually in the family meetings organized by the AECJD. The awarded two-year project aims to explore further novel ways of administration for a possible anti-prion molecule which needs to reach the central nervous system in sufficient amounts to be effective.
ATLAS Molecular Pharma awarded with the research grant ‘Cristina Pericàs Almendro’ 2018-2019 by the Spanish Association for Creutzfeldt-Jakob disease
Para compartir esta historia, elija cualquier plataforma
Related Posts
-
Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita Gallery
Atlas Molecular Pharma recibe la aprobación de la Administración de Drogas y Alimentos de los Estados Unidos de un medicamento huérfano para el tratamiento de la porfiria eritropoyética congénita
-
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the US Food & Drug Administration of an Orphan Drug for the treatment of Congenital Erythropoietic Porphyria
-
Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita Gallery
Atlas Molecular Pharma recibe la aprobación de la Comisión Europea de un medicamento huérfano para el tratamiento de la Porfiria Eritropoyética Congénita
-
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria Gallery
Atlas Molecular Pharma receives approval by the European Commission of an Orphan Medicinal Product for the treatment of Congenital Erythropoietic Porphyria